Tim Behrens is a physician-scientist who has studied the biology and human genetics of autoimmunity for over 35 years.  After Rheumatology subspecialty training and a postdoc at the NIH cloning B cell genes, he served on faculty at the Center for Immunology, University of Minnesota for 14 years.  In 2006, he began work at Genentech where he held a number of roles including head of exploratory clinical development (pre-IND to phase 2 POC) for non-oncology therapeutic areas and led groups for biomarker discovery/development and human genetics.  At Genentech, he contributed to the development of the PD-L1 inhibitor Tecentriq, the anti-CD20 Ocrelizumab for MS and the anti-IL-13 Lebrikizumab for atopy.  In 2017, Tim served on the founding team of Maze Therapeutics (South San Francisco) using human genetics to identify novel targets.  In 2021, he co-founded Human Immunology Biosciences (HIBio; South San Francisco) that licensed the clinical stage anti-CD38 mAb Felzartamab from MorphoSys AG for clinical development in autoimmunity; HiBio was purchased by Biogen in July 2024.  In 2023, Tim was appointed President of R&D for Nighthawk Therapeutics (San Diego) to develop therapies using a novel technology to tolerize human B cells.  He resides in Seattle and is a consultant for several early stage biotech companies. 

‍